|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Fedewa SA, Goding Sauer A,
Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015:
Convergence of incidence rates between black and white women. CA
Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nagini S: Breast cancer: Current molecular
therapeutic targets and new players. Anticancer Agents Med Chem.
17:152–163. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin CH, Chang CY, Lee KR, Lin HJ, Chen TH
and Wan L: Flavones inhibit breast cancer proliferation through the
Akt/FOXO3a signaling pathway. BMC Cancer. 15:9582015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shay JW: Role of telomeres and telomerase
in aging and cancer. Cancer Discov. 6:584–593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu B, Peng M and Song Q: The co-expression
of telomerase and ALT pathway in human breast cancer tissues.
Tumour Biol. 35:4087–4093. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kulić A, Plavetić ND, Gamulin S,
Jakić-Razumović J, Vrbanec D and Sirotković-Skerlev M: Telomerase
activity in breast cancer patients: Association with poor prognosis
and more aggressive phenotype. Med Oncol. 33:232016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu L, Zhang C, Zhu G, Irwin M, Risch H,
Menato G, Mitidieri M, Katsaros D and Yu H: Telomerase expression
and telomere length in breast cancer and their associations with
adjuvant treatment and disease outcome. Breast Cancer Res.
13:R562011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi Y, Sun L, Chen G, Zheng D, Li L and
Wei W: A combination of the telomerase inhibitor, BIBR1532, and
paclitaxel synergistically inhibit cell proliferation in breast
cancer cell lines. Target Oncol. 10:565–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu P, Shen X, Yang W, Zhang Y, Liu C and
Huang T: ZEB1 stimulates breast cancer growth by up-regulating
hTERT expression. Biochem Biophys Res Commun. 495:2505–2511. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aziz N, Kim MY and Cho JY:
Anti-inflammatory effects of luteolin: A review of in vitro, in
vivo, and in silico studies. J Ethnopharmacol. 225:342–358. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma L, Peng H, Li K, Zhao R, Li L, Yu Y,
Wang X and Han Z: Luteolin exerts an anticancer effect on NCI-H460
human non-small cell lung cancer cells through the induction of
Sirt1-mediated apoptosis. Mol Med Rep. 12:4196–4202. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin Y, Shi R, Wang X and Shen HM:
Luteolin, a flavonoid with potential for cancer prevention and
therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang MY, Wang CJ, Chen NF, Ho WH, Lu FJ
and Tseng TH: Luteolin enhances paclitaxel-induced apoptosis in
human breast cancer MDA-MB-231 cells by blocking STAT3. Chem Biol
Interact. 213:60–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tu SH, Ho CT, Liu MF, Huang CS, Chang HW,
Chang CH, Wu CH and Ho YS: Luteolin sensitises drug-resistant human
breast cancer cells to tamoxifen via the inhibition of cyclin E2
expression. Food Chem. 141:1553–1561. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin D, Kuang G, Wan J, Zhang X and Li H,
Gong X and Li H: Luteolin suppresses the metastasis of
triple-negative breast cancer by reversing
epithelial-to-mesenchymal transition via downregulation of
β-catenin expression. Oncol Rep. 37:895–902. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ganesan K and Xu B: Telomerase inhibitors
from natural products and their anticancer potential. Int J Mol
Sci. 19(pii): E132017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun DW, Zhang HD, Mao L, Mao CF, Chen W,
Cui M, Ma R, Cao HX, Jing CW, Wang Z, et al: Luteolin inhibits
breast cancer development and progression in vitro and in vivo by
suppressing notch signaling and regulating MiRNAs. Cell Physiol
Biochem. 37:1693–1711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kyo S, Takakura M, Fujiwara T and Inoue M:
Understanding and exploiting hTERT promoter regulation for
diagnosis and treatment of human cancers. Cancer Sci. 99:1528–1538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vageli D, Ioannou MG and Koukoulis GK:
Transcriptional activation of hTERT in breast carcinomas by the
Her2-ER81-related pathway. Oncol Res. 17:413–423. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lou L, Liu Y, Zhou J, Wei Y, Deng J, Dong
B and Chai L: Chlorogenic acid and luteolin synergistically inhibit
the proliferation of interleukin-1β-induced fibroblast-like
synoviocytes through regulating the activation of NF-κB and
JAK/STAT-signaling pathways. Immunopharmacol Immunotoxicol.
37:499–507. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Du Q, Yang Y, Wang J, Dou S, Liu
C and Duan J: The protective effect of Luteolin on myocardial
ischemia/reperfusion (I/R) injury through TLR4/NF-κB/NLRP3
inflammasome pathway. Biomed Pharmacother. 91:1042–1052. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen T, Li B, Xu Y, Meng S, Wang Y and
Jiang Y: Luteolin reduces cancer-induced skeletal and cardiac
muscle atrophy in a Lewis lung cancer mouse model. Oncol Rep.
40:1129–1137. 2018.PubMed/NCBI
|
|
26
|
Goel S, Wang Q, Watt AC, Tolaney SM,
Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, et al:
Overcoming therapeutic resistance in HER2-positive breast cancers
with CDK4/6 inhibitors. Cancer Cell. 29:255–269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hasanpourghadi M, Pandurangan AK and
Mustafa MR: Modulation of oncogenic transcription factors by
bioactive natural products in breast cancer. Pharmacol Res.
128:376–388. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park SH, Ham S, Kwon TH, Kim MS, Lee DH,
Kang JW, Oh SR and Yoon DY: Luteolin induces cell cycle arrest and
apoptosis through extrinsic and intrinsic signaling pathways in
MCF-7 breast cancer cells. J Environ Pathol Toxicol Oncol.
33:219–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cook MT, Liang Y, Besch-Williford C,
Goyette S, Mafuvadze B and Hyder SM: Luteolin inhibits
progestin-dependent angiogenesis, stem cell-like characteristics,
and growth of human breast cancer xenografts. Springerplus.
4:4442015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cook MT, Liang Y, Besch-Williford C and
Hyder SM: Luteolin inhibits lung metastasis, cell migration, and
viability of triple-negative breast cancer cells. Breast Cancer
(Dove Med Press). 9:9–19. 2016.PubMed/NCBI
|
|
31
|
Ding S, Hu A, Hu Y, Ma J, Weng P and Dai
J: Anti-hepatoma cells function of luteolin through inducing
apoptosis and cell cycle arrest. Tumour Biol. 35:3053–3060. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ren X, Zhang Z, Tian J, Wang H, Song G,
Guo Q, Tian J, Han Y, Liao Q, Liu G, et al: The downregulation of
c-Myc and its target gene hTERT is associated with the
antiproliferative effects of baicalin on HL-60 cells. Oncol Lett.
14:6833–6840. 2017.PubMed/NCBI
|
|
33
|
Bai D, Ueno L and Vogt PK: Akt-mediated
regulation of NFkappaB and the essentialness of NFkappaB for the
oncogenicity of PI3K and Akt. Int J Cancer. 125:2863–2870. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Papanikolaou V, Athanassiou E, Dubos S,
Dimou I, Papathanasiou I, Kitsiou-Tzeli S, Kappas C and Tsezou A:
hTERT regulation by NF-κB and c-myc in irradiated HER2-positive
breast cancer cells. Int J Radiat Biol. 87:609–621. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sabzichi M, Hamishehkar H, Ramezani F,
Sharifi S, Tabasinezhad M, Pirouzpanah M, Ghanbari P and Samadi N:
Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB
231 cells to doxorubicin by suppressing Nrf2 mediated signalling.
Asian Pac J Cancer Prev. 15:5311–5316. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jagadeesh S, Kyo S and Banerjee PP:
Genistein represses telomerase activity via both transcriptional
and posttranslational mechanisms in human prostate cancer cells.
Cancer Res. 66:2107–2115. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yeo M, Rha SY, Jeung HC, Hu SX, Yang SH,
Kim YS, An SW and Chung HC: Attenuation of telomerase activity by
hammerhead ribozyme targeting human telomerase RNA induces growth
retardation and apoptosis in human breast tumor cells. Int J
Cancer. 114:484–489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moon DO, Kim MO, Heo MS, Lee JD, Choi YH
and Kim GY: Gefitinib induces apoptosis and decreases telomerase
activity in MDA-MB-231 human breast cancer cells. Arch Pharm Res.
32:1351–1360. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moradzadeh M, Hosseini A, Erfanian S and
Rezaei H: Epigallocatechin-3-gallate promotes apoptosis in human
breast cancer T47D cells through down-regulation of PI3K/AKT and
Telomerase. Pharmacol Rep. 69:924–928. 2017. View Article : Google Scholar : PubMed/NCBI
|
